Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
Authors:
Open Access
- 19 May 2021
- journal article
- letter
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 41 (6) , 1169-1171
Abstract
No abstract availableFunding Information
- National Institute of Allergy and Infectious Diseases (5P01AI118688-04)
- National Institute of Diabetes and Digestive and Kidney Diseases (1F30DK123915-01)
- Chan Zuckerberg Biohub
- National Institute of General Medical Sciences (5T32GM007618-42)
- Howard Hughes Medical Institute
- The Rockefeller University
- St. Giles Foundation
- National Institutes of Health (R01AI088364)
- National Center for Advancing Translational Sciences
- NIH Clinical and Translational Science Award (UL1 TR001866)
- Fast Grant from Emergent Ventures
- Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (UM1HG006504 and U24HG008956)
- Fisher Center for Alzheimer’s Research Foundation
- Meyer Foundation
- French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01)
- Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID)
- French Foundation for Medical Research (EQU201903007798)
- RM and ANR GENCOVID project
- ANRS-COV05
- Square Foundation
- Grandir - Fonds de solidarité pour l’enfance
- SCOR Corporate Foundation for Science
- Institut National de la Santé et de la Recherche Médicale
- University of Paris
This publication has 5 references indexed in Scilit:
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19New England Journal of Medicine, 2021
- Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19bioRxiv, 2021
- (A Little) Clarity on Convalescent Plasma for Covid-19New England Journal of Medicine, 2021
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasmabioRxiv, 2021
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020